Advertisement


Fabrice Andre, MD, PhD, on Breast Cancer: Interim Analysis From DESTINY-Breast07

2024 ASCO Annual Meeting

Advertisement

Fabrice Andre, MD, PhD, of Gustave Roussy and the Université Paris-Saclay, discusses a dose-expansion interim analysis of trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer (Abstract 1009).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
HER2 overexpression breast cancer represents around 20% of patients with metastatic breast cancer. The outcome in recent trials is around 50 to 60 months median overall survival with the first-line therapy being Taxane plus Trastuzumab plus Pertuzumab, and this combination provides around 18 months progression-free survival. In this context, there is a need to improve the outcome of these patients. Trastuzumab Deruxtecan is a new drug, it is an antibody-drug conjugate that targets HER2. This drug has shown efficacy in patients who present with HER2 overexpression metastatic breast cancer, previously treated with Taxane Pertuzumab Trastuzumab. In this context, the question is whether giving Trastuzumab Deruxtecan in the first-line setting could improve the outcome of patients. Before moving to the Phase IV / Phase III, it was necessary to run the Phase I / Phase II to explore the safety and preliminary signal of efficacy. In DESTINY-Breast07 Phase I / Phase II, 75 patients were included in the first-line setting to receive Trastuzumab Deruxtecan. 50 patients were included again in the first-line setting to receive Trastuzumab Deruxtecan plus Pertuzumab. What are the results? The response rate was 76% in patients who received Trastuzumab Deruxtecan single agent, and was 84% in the group of patients who received Trastuzumab Deruxtecan plus Pertuzumab. In terms of progression-free survival, it's too early to conclude. Nevertheless, more than 80% of the patients, whether they were treated with Trastuzumab Deruxtecan or T-DXd plus Pertuzumab, more than 80% of the patients had a progression-free survival more than 12 months. Meaning that the disease is controlled for the vast majority of patients for more than 12 months. Then in terms of subgroup, there was no difference of efficacy according to the expression of hormone receptor or whether the disease was recurrent after adjuvant therapy or de novo. In terms of safety, around 10% of patients presented with ILD, which is lung toxicity. Nevertheless, no toxic death was observed. One toxicity that was moderate, but that was increased with Pertuzumab, was diarrhea, but still the number and the percentage are very small. So what can we say about this study? It's a Phase I / Phase II study that tells us that in the first-line setting, T-DXd or T-DXd plus Pertuzumab, provides encouraging preliminary signal of efficacy, and that was the rationale to start a Phase III trial testing this new drug in the first-line setting as compared to the standard of care, and hopefully will improve the outcome of the patients.

Related Videos

Issues in Oncology

Andrew Srisuwananukorn, MD, and Alexander T. Pearson, MD, PhD, on Artificial Intelligence in the Clinic: Understanding How to Use This 21st Century Tool

Andrew Srisuwananukorn, MD, of The Ohio State University, and Alexander T. Pearson, MD, PhD, of the University of Chicago, discuss the use of artificial intelligence (AI) in the clinic, its potential benefits in diagnosis and treatment, resources available to help physicians learn more about AI, and what’s coming for the next generation of medical school students.

Lung Cancer

Heather Wakelee, MD, on NSCLC: IMpower010 Survival Results After Long-Term Follow-up of Atezolizumab vs Best Supportive Care

Heather Wakelee, MD, of Stanford University Medical Center, discusses phase III findings showing that the disease-free survival benefit with adjuvant atezolizumab continues to translate into a positive overall survival trend vs best supportive care in patients with stage II–IIIA non–small cell lung cancer (NSCLC). These results further support the use of adjuvant atezolizumab in PD-L1–selected populations, according to Dr. Wakelee (LBA8035).

Multiple Myeloma

Suzanne Trudel, MD, on Multiple Myeloma: Results From the DREAMM-8 Study of Treatments After Relapse

Suzanne Trudel, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with relapsed or refractory multiple myeloma who had one or more prior lines of treatment, belantamab mafodotin-blmf plus pomalidomide and dexamethasone improved progression-free survival and showed a favorable overall survival trend compared with pomalidomide plus bortezomib and dexamethasone.

Breast Cancer

Eva M. Ciruelos, MD, PhD, on HER2-Positive and PAM50 Luminal Breast Cancer: Primary Results From the PATRICIA Trial

Eva M. Ciruelos, MD, PhD, of Spain’s Hospital 12 de Octubre and the Instituto de Investigación Sanitaria Hospital 12 de Octubre, discusses phase II data showing that the combination of palbociclib, trastuzumab, and endocrine therapy improved progression-free survival in patients with previously treated PAM50 luminal A or B, HER2-positive advanced breast cancer, as compared with treatment of physicians’ choice (Abstract 1008).

Breast Cancer

Lisa A. Carey, MD, and Dejan Juric, MD, on Breast Cancer: Updates From the INAVO120 Trial

Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Dejan Juric, MD, of the Massachusetts General Hospital Cancer Center, discuss phase III findings on first-line use of inavolisib or placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer who relapsed within 12 months of completing adjuvant endocrine therapy (Abstract 1003).

Advertisement

Advertisement




Advertisement